drugset / Trial / NCT07376629
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial is a Phase II study. The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of HB0025 administered with chemotherapy in participants with locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic breast cancer (mBC).
Timeline
- Start
- 2025-08-14
- Primary completion
- 2027-01-15
- Completion
- 2027-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB0025 | Monoclonal antibody | 10 mg/kg | — |
| Subject | HB0025 | Monoclonal antibody | 20 mg/kg | — |
| Background | Paclitaxel | Small molecule | — | — |